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The transplant community is divided regarding whether substitution with generic im-
munosuppressants is appropriate for organ transplant recipients. We estimated the 
rate of uptake over time of generic immunosuppressants using US Medicare Part D 
Prescription Drug Event (PDE) and Colorado pharmacy claims (including both Part D 
and non- Part D) data from 2008 to 2013. Data from 26 070 kidney, 15 548 liver, and 
6685 heart recipients from Part D, and 1138 kidney and 389 liver recipients from 
Colorado were analyzed. The proportions of patients with PDEs or claims for generic 
and brand- name tacrolimus or mycophenolate mofetil were calculated over time by 
transplanted organ and drug. Among Part D kidney, liver, and heart beneficiaries, the 
proportion dispensed generic tacrolimus reached 50%- 56% at 1 year after first ge-
neric approval and 78%- 81% by December 2013. The proportion dispensed generic 
mycophenolate mofetil reached 70%- 73% at 1 year after generic market entry and 
88%- 90% by December 2013. There was wide interstate variability in generic uptake, 
with faster uptake in Colorado compared with most other states. Overall, generic 
substitution for tacrolimus and mycophenolate mofetil for organ transplant recipients 
increased rapidly following first availability, and utilization of generic immunosup-
pressants exceeded that of brand- name products within a year of market entry.
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1  | INTRODUC TION
To reduce the risk of graft rejection and loss after organ transplanta-
tion, transplant recipients must have access to immunosuppressive 
medications (ISMs). ISM costs can be a substantial burden for trans-
plant patients, potentially limiting access and increasing nonad-
herence.1,2 The use of therapeutically equivalent generic products 
can reduce recipients’ and payers’ financial burdens. However, the 
     |  1765LIU et aL.
transplant community has expressed concerns about generic sub-
stitution for brand- name ISMs and the substitution of one generic 
product for another.2-7 In addition, patients may not believe generic 
ISMs are equivalent to their brand- name counterparts and may not 
be receptive to payer- driven generic substitution.2,8 Previous ge-
neric vs brand- name ISM comparison studies are limited by small 
sample sizes, retrospective designs, inclusion of only healthy volun-
teers, or inconsistent results across studies.6,9-13
Results from bioequivalence studies and expected cost savings 
associated with generic ISMs have led several US and international 
professional transplant societies to issue guidelines advocating for 
generic ISM substitution.3,14,15 If all prescription requirements are 
met, generic substitution can even be carried out without pre-
scriber or patient input in some states.6,16-18 Generic- for- brand 
or generic- for- generic substitutions can also confuse patients. 
Different versions of a drug can have different appearances, 
which may lead to increased risk of medication errors and non-
adherence.6 Partly due to these concerns, the aforementioned 
guidelines all recommend that generic substitution of ISMs only 
be implemented with frequent patient monitoring, patient educa-
tion on differences between products, and caution under certain 
clinical conditions.
The most widely used ISMs by US organ transplant recipients 
are tacrolimus (TAC) and mycophenolate mofetil (MMF).19 The first 
generic versions of MMF and TAC were approved by the US Food 
and Drug Administration (FDA) in July 2008 and August 2009, re-
spectively. A 2013 Drug Trend Report from a prescription benefit 
plan provider estimated generic mycophenolate (did not specify 
MMF or mycophenolate sodium [MPS]) and TAC to capture 33.5% 
and 30.7% of the total market share of all transplant medications, 
compared to 7.4% for brand- name mycophenolic acid and 7.2% for 
brand- name TAC.20 However, there is little additional information 
on the penetration of generic TAC and MMF or on trends in use 
over time.
In this study, we used the Scientific Registry of Transplant 
Recipients (SRTR), national Medicare Part D Prescription Drug 
Events (PDEs), and the Colorado All- Payer Claims Database (CO- 
APCD) to describe dispensing patterns for generic and brand- name 
ISMs from 2008 to 2013 for kidney, liver, and heart transplant re-
cipients. Our primary objective was to describe the trajectory of 
uptake of generic TAC and MMF over time in a national sample of 
transplant recipients. Our secondary objective was to investigate 
state- by- state variation in uptake of generic ISMs.
2  | MATERIAL S AND METHODS
2.1 | Study design and data sources
Scientific Registry of Transplant Recipients, a national registry of 
organ transplantation data, was used to identify all pediatric and 
adult kidney, liver, and heart transplant recipients in the United 
States between 1987 and 2013. These data were linked to national 
Medicare Part D PDE data to identify TAC and MMF prescriptions 
filled between January 2008 and December 2013 for transplant re-
cipients whose ISMs were covered by Part D. The prescription pe-
riod from 2008 to 2013 was chosen to correspond to the years after 
FDA approvals for the first generic MMF and TAC products. Part 
D data were used because they include the National Drug Code 
(NDC) for ISMs, which differentiates between generic and brand- 
name products. Part B (another source of coverage for ISMs) data 
were not examined because they do not include the NDCs neces-
sary to distinguish generic from brand- name PDEs. Eligibility for 
ISM coverage by Medicare Part B vs Medicare Part D is detailed in 
Supplement I.
SRTR data were also linked to the CO- APCD to obtain claims 
for prescription ISMs filled in Colorado from January 2009 through 
September 2014. The CO- APCD was used because it contains NDCs 
for claims from both Part D and non- Part D patients, including most 
claims paid by commercial insurance carriers, Medicare, Medicare 
Advantage plans, and Medicaid for Colorado residents since 2009.
Analyses were carried out separately for Part D and CO- APCD 
data by organ and drug type. In Part D, TAC and MMF PDEs for kid-
ney, liver, and heart were analyzed. In the CO- APCD, only liver TAC 
and kidney TAC and MMF claims were analyzed due to small sample 
sizes of the other organ- drug combinations.
2.2 | Study sample
Patients were eligible for primary analyses if they (1) received a 
single- organ kidney, liver, or heart transplant (ie, simultaneous mul-
tiple organ transplants were excluded) between 1987 and 2013 and 
maintained graft function for 30 days following transplantation; 
(2) had graft function on January 1, 2008 for those who received 
their transplant before 2008; and (3) had at least 1 posttransplant 
TAC or MMF PDE or pharmacy claim during the study period. Graft 
function was defined as the absence of all- cause graft failure, in-
cluding repeat transplantation or death for kidney, liver, and heart 
recipients, and additionally return to dialysis for kidney recipients.
2.3 | Outcome variables
Our primary outcome was brand- name or generic PDEs or pharmacy 
claims for TAC and MMF. As our focus was uptake of generic ISMs 
among transplant recipients, we did not assess conversions from ge-
neric to brand or between different types of generic ISM products.
Mycophenolate sodium is used as an alternative to MMF in some 
transplant recipients; however, MPS was not included in the main 
analysis because the first MPS generic application was approved by 
the FDA late in our study period (2012).
2.4 | Independent variables
Due to our interest in adoption rates of generic ISMs over time, 
our primary independent variable was calendar month. In addi-
tional analyses, we stratified national Medicare Part D PDE data 
by the state where transplants occurred and assessed associations 
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between generic uptake and state pharmacy laws. For the latter, we 
used the Survey of Pharmacy Laws to categorize states as having 
mandatory vs permissive generic substitution laws and as requir-
ing patient consent or notification of generic substitution or not.18 
Colorado in particular required patient consent and did not mandate 
generic substitution. Additional independent variables were ex-
plored in sensitivity analyses (Supplement III).
2.5 | Statistical analysis
For each analysis, we calculated the percentage of patients dis-
pensed brand- name or generic ISMs by calendar month for the en-
tire study period. Patients dispensed both brand- name and generic 
products in the same month were counted as one half for each. For 
each percentage, a 95% confidence interval (CI) was calculated using 
the Wilson score method.21 Reference lines in the graphs indicate 
approval dates of generic products to facilitate interpretation. FDA 
approvals for different generic ISM dosage forms or strengths under 
the same application number or application holder were grouped 
and the earliest generic approval date was used.
Using Part D PDEs, we also calculated percentages of ISM pre-
scriptions filled with generic products over time for kidney and liver 
recipients in each US state and Washington, DC. States with less 
than 20 transplant patients prescribed the ISM during a given month 
were excluded from analysis for that month due to imprecision of 
percentage estimates. We did not perform this analysis for heart re-
cipients because half or more states had less than 20 patients during 
most calendar months.
To evaluate whether yearly state- level uptake of generic ISM was 
associated with differences in state laws governing generic substi-
tution, we used linear generalized estimating equation models with 
sandwich- type standard error estimators to account for correla-
tions among years within states, adjusting for calendar year. States 
with less than 20 patients in a year were excluded from that year’s 
analyses.
All analyses were conducted using SAS version 9.4 (SAS Institute, 
Inc., Cary, NC).
3  | RESULTS
There were 26 070 kidney, 15 548 liver, and 6685 heart trans-
plant recipients enrolled in Part D who met study eligibility criteria 
(Figure 1), accounting for 7.6%, 13.5%, and 11.8% of all kidney, liver, 
and heart transplant recipients since 1987, respectively. These re-
cipients were mostly male, white, aged 50- 64 years (Table 1), and 
generally older and received their transplant less recently than the 
transplant population not enrolled in Part D (Supplement II). In the 
CO- APCD, 1138 kidney and 389 liver recipients were included in the 
analysis and were similar to the Part D cohort (see Supplement II for 
additional demographic and clinical data on both cohorts).
Among Part D beneficiaries with PDEs for TAC (generic or brand 
name), the proportion of kidney, liver, and heart recipients with 
PDEs for generic TAC reached 56%, 50%, and 51%, respectively, 
at 1 year after approval of the first generic TAC product (Figure 2). 
In contrast, generic MMF was unavailable until 9 months after the 
approval date of the first generic product. However, after 1 year of 
entering the market, the proportion dispensed generic MMFs (out of 
all MMF PDEs) increased to 73%, 70%, and 71% for kidney, liver, and 
heart recipients, respectively. By December 2013, across organs, 
78- 81% and 88- 90% of recipients with PDEs for TAC and MMF were 
dispensed the generic products, respectively. For both ISM types, 
F IGURE  1  Inclusion and exclusion of transplant recipients in Medicare Part D data. These charts show the total number of transplant 
recipients and the numbers excluded from analyses because of graft failure within 30 days from transplant, multiorgan transplantation, graft 
failure before 2008 (the start of our data period), or absence of Part D PDEs, and the number of subjects included in the final analyses by 
each organ type. The denominator for each percentage is the number of transplant recipients recorded in the SRTR during the study period 
(top box). *Graft failure was defined as the earliest of graft failure indicator from SRTR, re- transplantation, or death. PDEs, Prescription Drug 
Events; SRTR, Scientific Registry of Transplant Recipients
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TABLE  1 Descriptive statistics of transplant recipients by data source and organ type
Data source  
Organ type
Medicare part D Colorado APCD
Kidney Liver Heart Kidney Liver
Number of transplant 
recipientsa
26 070 15 548 6685 1138 389
Number of transplants 26 170 15 622 6705 1147 389
Year of transplantd
1987- 1990 0.8% (208) 1.4% (210) 1.8% (121)
3.3% (37) 5.9% (23)
1991- 1995 3.6% (944) 6.3% (979) 7.7% (517)
1996- 2000 15.3% (3978) 16.7% (2602) 19.6% (1307) 9.7% (110) 12.3% (48)
2001- 2005 31.4% (8195) 29.4% (4576) 28.4% (1899) 23.6% (268) 21.3% (83)
2006- 2010 39.3% (10 242) 36.0% (5605) 33.2% (2221) 37.6% (428) 33.2% (129)
2011- 2013 9.6% (2503) 10.1% (1576) 9.3% (620) 25.9% (295) 27.2% (106)
Male 57.2% (14 925) 60.6% (9429) 72.7% (4863) 56.2% (639) 62.0% (241)
Racee
White 51.9% (13 524) 71.7% (11 151) 72.2% (4827) 61.9% (704) 71.0% (276)
Black 24.9% (6493) 8.5% (1318) 16.9% (1128) 10.6% (121) 3.6% (14)
Hispanic 16.0% (4179) 14.6% (2272) 8.0% (536) 23.5% (267) 21.3% (83)
Asian/Other 7.2% (1873) 5.2% (802) 2.9% (194) 4.0% (46) 4.1% (16)
Age, years
Median (IQR) 52 (39–61) 54 (48–60) 54 (45–60) 47 (33- 58) 50 (39- 57)
<18 3.8% (993) 0.9% (143) 1.6% (106) 6.8% (77) 6.7% (26)
18- 34 14.4% (3760) 5.2% (809) 10.4% (697) 19.7% (224) 13.6% (53)
35- 49 25.3% (6587) 24.4% (3789) 23.1% (1546) 28.6% (326) 28.8% (112)
50- 64 42.7% (11 129) 61.5% (9566) 57.1% (3818) 32.5% (370) 46.5% (181)
≥65 13.8% (3601) 8.0% (1241) 7.7% (518) 12.4% (141) 4.4% (17)
BMI, kg/m2e
<18.5 4.5% (1026) 2.5% (361) 4.1% (257) 8.1% (87) 7.5% (29)
≥18.5 to <25.0 35.3% (8056) 29.7% (4276) 37.3% (2365) 37.7% (407) 37.9% (146)
≥25.0 to <30.0 32.1% (7317) 35.2% (5071) 36.9% (2340) 31.7% (342) 32.2% (124)
≥30.0 28.1% (6416) 32.7% (4713) 21.7% (1376) 22.6% (244) 22.3% (86)
Transplant typec,e
Donation after circulatory 
death
5.1% (1297) 3.1% (454) 6.6% (74) 3.7% (14)
Donation after brain death 57.0% (14 588) 93.5% (13 902) 49.5% (555) 89.8% (336)
Living related donation 25.7% (6583) 2.5% (379) 25.9% (290)
6.4% (24)
Living unrelated donation 12.2% (3124) 0.9% (137) 18.0% (202)
Previous transplant of the 
same organ type
10.9% (2850) 5.6% (867) 2.1% (143) 9.2% (105) 2.6% (10)
Number of HLA mismatches: 
1- 6 vs 0e
87.8% (22 515) 88.9% (1005)
Recipient diagnosis (kidney)e
Diabetes 22.5% (5813) 21.5% (243)
Hypertension 22.2% (5743) 13.1% (148)
Glomerulonephritis 25.4% (6559) 32.3% (365)
Cystic kidney disease 8.8% (2280) 11.2% (127)
Other 21.1% (5446) 21.9% (248)
(Continues)
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adoption patterns for generic products were similar across organ 
type.
In the CO- APCD, 74% and 78% of kidney and liver recipients 
were dispensed generic TAC at 1 year after first generic approval, 
respectively; and 80% of kidney recipients were dispensed generic 
MMF at 1 year after first generic market entry. By December 2013, 
90% and 89% of kidney and liver recipients were dispensed generic 
TAC, respectively; and 95% of kidney recipients were dispensed ge-
neric MMF.
Results from sensitivity analyses showed that brand- name ISM 
prescriptions were more likely to have dispense as written (DAW) 
codes that precluded generic substitution, including prescriber and 
patient preferences, while other factors did not appear to affect ge-
neric uptake (Supplement III).
Part D PDE analyses by state showed large interstate variability 
in uptake of generic ISMs (Figure 3). At 1 year after first generic TAC 
approval, the range between the 10th and 90th percentiles in uptake 
across states was 34 and 47 percentage points among kidney and 
liver recipients, respectively. Similarly, the range at 1 year after first 
generic MMF entry was 37 and 26 percentage points among kid-
ney and liver recipients, respectively. Additionally, the percentage 
of generic ISMs dispensed in December 2013 also varied by state. 
The range between the 10th and 90th percentiles across states 
was 27 and 28 percentage points for TAC and 18 and 17 percent-
age points for MMF, among kidney and liver recipients, respectively. 
States with the highest percentages of generic TAC ISMs dispensed 
at 1 year after generic approval included Colorado, Arizona, Oregon, 
and Washington (Figure 4). States with the highest percentages of 
generic MMF ISMs dispensed at 1 year after generic market entry 
included Colorado, Washington, Hawaii, and Missouri. No clear as-
sociation between patient consent regulations and generic uptake 
was detected (Figure S4); and mandatory generic substitution, al-
though not reaching statistical significance, was weakly associated 
with lower generic uptake.
4  | DISCUSSION
Post- FDA approval, the proportion of patients with PDEs for ge-
neric ISMs increased rapidly and exceeded those with PDEs for 
brand- name ISMs within 1 year. For TAC, generic uptake began 
soon after the first FDA approval of a generic product while ge-
neric MMF uptake did not begin until after the approval of several 
generic versions. This difference can be explained by the timing 
of brand- name patent expiration relative to FDA approval dates 
of these generic products. Expiration of the US patent for brand- 
name TAC (Prograf, Patent No. 4894366) preceded the first FDA 
approval date for generic TAC by 1 year, allowing generic TAC 
uptake to begin immediately following FDA approval. In contrast, 
the first FDA approval dates for generic MMF were in 2008 but 
Data source  
Organ type
Medicare part D Colorado APCD
Kidney Liver Heart Kidney Liver
Recipient diagnosis (liver)b,e
Acute hepatic necrosis 5.9% (919) 4.4% (17)
Cholestatic liver disease/
cirrhosis
12.7% (1969) 17.5% (68)
Noncholestatic cirrhosis 50.0% (7776) 46.3% (180)
Hepatitis C 40.3% (6271) 38.3% (149)
Malignant neoplasm 17.6% (2744) 23.4% (91)
Metabolic disease 3.7% (572) 3.6% (14)
Other liver disease 14.6% (2267) 9.0% (35)
Recipient diagnosis (heart)e
Coronary artery disease 42.6% (2845)
Cardiomyopathy 50.0% (3335)
Congenital/valvular/other 7.4% (496)
Ventricular assist device 
(heart)e
38.1% (1710)
APCD, All- Payer Claims Database; HLA, human leukocyte antigen; IQR, interquartile range.
aFor Colorado liver patients, only those with tacrolimus claims were included.
bDiagnoses for liver transplant recipients are based on both primary and secondary diagnoses and are not mutually exclusive. Each liver recipient can 
have 1 or 2 diagnoses; therefore, percentages will not sum to 100%.
cFor Colorado APCD liver patients, living related and unrelated donations were combined to suppress cells with n < 10.
dFor Colorado APCD patients, transplant years 1987 to 1990 and 1991 to 1995 were combined into 1 group to suppress cells with n < 10.
eMissing for at most 5% of patients, except BMI missing for 7% and 12% of Medicare part D liver and kidney patients, respectively, and ventricular assist 
device missing for 33% of Medicare part D heart patients.
TABLE  1  (Continued)
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the patent for brand- name MMF (CellCept, Patent No. 4753935) 
did not expire until May 3, 2009. Therefore, the first generic MMF 
drugs were not dispensed until 2009.
Faster uptake of generic ISMs was observed in the CO- APCD 
compared with national averages from Part D. This result was con-
sistent with our Part D state- level analyses, which showed different 
rates of generic ISM uptake by state. Our results did not support 
our hypothesis that differences in state regulations on dispensing 
of generic medications might explain this interstate variability. In 
Colorado specifically, state pharmacy law requires patient consent 
for generic substitution and does not mandate generic substitution 
(ie, generic substitution is permissive), yet Colorado was one of the 
states with the highest generic ISM uptake rates. Differences across 
states in socioeconomic status of organ transplant recipients, access 
to health care, and payer behavior could also have influenced the 
generic uptake rates in Colorado.
F IGURE  2 Percent of patients dispensed generic vs brand- name immunosuppressants over time. Each vertical line marks the date of 
FDA US Food and Drug Administration approval of a generic tacrolimus or mycophenolate mofetil product. The 95% confidence intervals for 
the percentages are displayed as gray bands. APCD, All- Payer Claims Database
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Market penetration of generic MMFs at 1 year was comparable 
to averages observed among other medications with first generic 
entry in 2008 or 2009, while generic TAC uptake was more grad-
ual.22 This difference may reflect some practitioners’ initial hesi-
tancy to allow patients to switch to generic TAC given that TAC is a 
narrow therapeutic index (NTI) medication,2,23 whereas MMF is not. 
NTI status implies greater risk of adverse clinical consequences from 
too high or too low drug concentrations.2,7,17,24 Thus, until therapeu-
tic equivalency is confirmed in clinical practice, there may be more 
apprehension about the efficacy of generic versions of NTI medica-
tions such as TAC.2,25
Our study found that uptake of generic ISMs was largely in-
fluenced by generic market entry and calendar time. Adoption of 
generic ISMs did not appear to depend on time elapsed since trans-
plant. The uptake patterns for each generic ISM was consistent 
across types of transplanted organs.
Additionally, market forces may have influenced the uptake of ge-
neric ISMs. For example, by adding the generic product to its formulary 
with lower patient copayments, payers may incentivize generic ISM 
use.22 Pharmaceutical industry practices such as patient copay as-
sistance programs (data unavailable) may also influence generic up-
take.26,27 Furthermore, prescriber practices and patient preferences 
appear to have affected brand- name vs generic prescriptions substan-
tially, as observed from our sensitivity analysis of DAW status of PDEs 
for brand- name ISMs. Generic substitution at the pharmacy is not 
mandatory in all states;18 thus it is possible that pharmacy practices 
(unavailable in our data) may also affect selection of generic products.
Introduction of generic drug products is expected to reduce 
costs for payers and patients, potentially increasing access and ad-
herence. Assessment of these benefits in transplantation necessi-
tates exploration of the longitudinal use of generic ISMs, which has 
not previously been reported. As more transplant recipients use ge-
neric ISMs, the potential cost savings to both payers and patients 
may increase. Since ISM costs paid by patients may exceed $500/
month7 and overall ISM costs may exceed $4000/month,2 the mag-
nitude of the potential cost savings could be substantial.
F IGURE  3 State- level variability in uptake of generic tacrolimus (TAC) and mycophenolate mofetil (MMF). Panels A and B show the 
percent uptake of generic TAC or MMF among kidney transplant recipients. Panels C and D show the percent uptake of generic TAC or MMF 
among liver transplant recipients. Data from states with fewer than 20 kidney or liver transplant recipients with TAC or MMF prescription 
drug events in the Medicare Part D database are not shown
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Our study has several strengths, including use of multiple data 
sources with monthly data spanning multiple years after the intro-
duction of generic ISMs. The CO- APCD includes transplant recipi-
ents covered by a large variety of payers. The Part D data represent 
a large national sample of Medicare beneficiaries. Using both data 
sources and sensitivity analyses, we were able to confirm robustness 
of results.
Our study also has limitations. Since we only analyzed data from 
CO- APCD and Part D, generalizability of results to the larger US 
transplant population or the overall Medicare transplant population 
is uncertain. Our analysis of the Medicare population was limited to 
Part D PDEs, since the NDCs necessary to differentiate between 
brand- name and generic products are unavailable in Part B. Thus, 
although Medicare Part B is a common payer for ISMs among trans-
plant recipients, particularly kidney recipients during the first 3 
years posttransplant, Part B data cannot be used to analyze uptake 
of generic ISMs. Given that Medicare Part D plans often encourage 
use of generic products28,29 while Medicare Part B may not,30 it is 
possible that our results are only applicable to Part D beneficiaries 
rather than the entire Medicare population.
In addition, we did not have data on adherence, limiting in-
terpretation of our results to dispensing of generics rather than 
actual use. Finally, only a portion of each patient’s follow- up pe-
riod, particularly within the Part D database, was accounted for in 
our data. Missing data could have several explanations, including 
(1) patients’ ISM prescriptions were paid by sources not included 
F IGURE  4 Percent of patients dispensed generic immunosuppressants at 1 year after national generic approval and market entry.  
Panels A and B show percent uptake of generic tacrolimus (TAC) or mycophenolate mofetil (MMF) among kidney transplant recipients. 
Panels C and D show percent uptake of generic TAC and MMF among liver transplant recipients. Data from states with fewer than 20 kidney 
or liver transplant recipients with TAC or MMF prescription drug events in the Medicare Part D database are not shown
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in the available databases; (2) patients switched to different types 
of ISMs or stopped using the classes of ISMs analyzed; (3) patients 
had decreases in dosage or accumulated a surplus of ISMs that 
allowed them to use existing prescriptions for longer than the 
original days’ supply; or (4) incompleteness in data acquisition. 
However, it is unlikely that these scenarios would introduce bias 
in our results, because none of them would be expected to occur 
at a different rate over time for brand- name compared with ge-
neric ISMs.
Our study demonstrates rapid uptake and high proportions of 
dispensed generic TAC and MMF, as well as wide interstate variabil-
ity in generic ISM penetration. The impetus of generic adoption is 
presumably cost savings to both patients and payers. Research is 
currently in progress to assess changes in ISM costs for transplant 
recipients following the introduction of generic ISMs. Further study 
into the potential relationship between generic uptake and graft out-
comes is also warranted.
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